Suppr超能文献

家族性淀粉样多神经病患者肝移植后的玻璃体淀粉样变性:突变型转甲状腺素蛋白的眼部合成

Vitreous amyloidosis after liver transplantation in patients with familial amyloid polyneuropathy: ocular synthesis of mutant transthyretin.

作者信息

Munar-Qués M, Salva-Ladaria L, Mulet-Perera P, Solé M, López-Andreu F R, Saraiva M J

机构信息

Grupo de Estudio de la PAF, Palma de Mallorca, Spain.

出版信息

Amyloid. 2000 Dec;7(4):266-9. doi: 10.3109/13506120009146440.

Abstract

Vitreous amyloidosis has been reported in patients with familial amyloidotic polyneuropathy (FAP) who are carriers of different mutant transthyretins (TTR). The mutant TTR constitutes the majority of the amyloid vitreous fibrils in heterozygous Val30Met patients. Due to the ocular synthesis of TTR, it is possible that the retina constitutes the source of vitreous amyloid fibrils, if so, orthotopic liver transplantation (OLT) performed to remove the mutant TTR from circulation might not be effective in treating/avoiding vitreous amyloid. We present vitreous amyloidosis in a FAP patient from Maiorca with ATTR Val30Met who underwent OLT at age 38. Progressive impairment of visual acuity (VA) appeared bilaterally 2 years after OLT due to vitreous opacities consistent with amyloid; successful bilateral vitrectomy was performed. Amyloid was demonstrated in the vitrectomy material by Congo red staining, immunohistochemistry and Western blotting analyses were positive with an antibody for human TTR. Mass spectrometry of TTR revealed the presence of the mutant in approximately 20% of the TTR. Future structural studies on vitreous material with different proportions of normal/versus mutant TTR might shed some light on TTR fibrillogenesis. These results show that vitreous deposition of TTR amyloidfibrils occurs after OLT, suggesting that ongoing intraocular synthesis of mutant TTR might contribute to this process. We also present the progression after OLT of vitreous amyloidosis previously diagnosed in three patients with TTR Val71Ala.

摘要

玻璃体淀粉样变性已在患有家族性淀粉样多神经病(FAP)且携带不同突变型转甲状腺素蛋白(TTR)的患者中被报道。在杂合子Val30Met患者中,突变型TTR构成了淀粉样玻璃体原纤维的大部分。由于TTR在眼部合成,如果视网膜是玻璃体淀粉样原纤维的来源,那么进行原位肝移植(OLT)以从循环中清除突变型TTR可能对治疗/避免玻璃体淀粉样变性无效。我们报告了一名来自马略卡岛的患有ATTR Val30Met的FAP患者的玻璃体淀粉样变性,该患者在38岁时接受了OLT。OLT后2年,由于与淀粉样变性一致的玻璃体混浊,双眼视力(VA)出现进行性损害;成功进行了双侧玻璃体切除术。通过刚果红染色在玻璃体切除材料中证实了淀粉样变性,免疫组织化学和蛋白质印迹分析用人TTR抗体呈阳性。TTR的质谱分析显示在大约20%的TTR中存在突变体。对具有不同比例正常/与突变型TTR的玻璃体材料进行的未来结构研究可能会为TTR纤维形成提供一些线索。这些结果表明,OLT后发生了TTR淀粉样原纤维的玻璃体沉积,提示突变型TTR的持续眼内合成可能促成了这一过程。我们还展示了先前诊断为TTR Val71Ala的三名患者在OLT后玻璃体淀粉样变性的进展情况。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验